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Abstract 
Epidemiological studies suggest a link between type-2 diabetes and Parkinson’s disease (PD) risk. Treatment of 
type-2 diabetes with insulin sensitizing drugs lowers the risk of PD. We previously showed that the insulin sen-
sitizing drug, MSDC-0160, ameliorates pathogenesis in some animal models of PD. MSDC-0160 reversibly binds 
the mitochondrial pyruvate carrier (MPC) protein complex, which has an anti-inflammatory effect and restores 
metabolic deficits. Since PD is characterized by the deposition of α-synuclein (αSyn), we hypothesized that in-
hibiting the MPC might directly inhibit αSyn aggregation in vivo in mammals. To answer if modulation of MPC 
can reduce the development of αSyn assemblies, and reduce neurodegeneration, we treated two chronic and 
progressive mouse models; a viral vector-based αSyn overexpressing model and a pre-formed fibril (PFF) αSyn 
seeding model with MSDC-0160. These two models present distinct types of αSyn pathology but lack inflamma-
tory or autophagy deficits. Contrary to our hypothesis, we found that a modulation of MPC in these models did 
not reduce the accumulation of αSyn aggregates or mitigate neurotoxicity. Instead, MSDC-0160 changed the 
post-translational modification and aggregation features of αSyn. These results are consistent with the lack of a 
direct effect of MPC modulation on synuclein clearance in these models. 
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Synucleinopathies are age-related neuro-
degenerative diseases characterized by α-synuclein 
(αSyn) protein misfolding, inflammation and meta-
bolic deficits. People with Parkinson’s disease (PD), 
dementia with Lewy bodies (DLB) and multiple 
system atrophy (MSA) present with peripheral and 
central synucleinopathies that coincide with a wide 
range of non-motor (e.g., hyposmia, constipation 
and rapid eye movement sleep behavior disorder) 
and classical motor symptoms1. The disease mech-
anisms underlying synucleinopathies are not com-
pletely understood, but evidence suggests that 
mitochondrial dysfunction, neuroinflammation and 
altered protein homeostasis all play a role, as re-
viewed in detail elsewhere2. 
Epidemiological studies have indicated a link 
between PD and type 2 diabetes3-5. Type 2 diabetes 
is associated with a 38% increased risk of develop-
ing PD3,4. On a molecular level, both people with PD 
and those with type 2 diabetes have similar meta-
bolic abnormalities such as mitochondrial dysfunc-
tion and insulin resistance5. Given these links be-
tween PD and metabolic dysfunction, clinical trials 
in PD were initiated to test drugs already approved 
for the treatment of diabetes. In a randomized, 
double-blinded placebo-controlled trial with the 
brain penetrant insulin sensitizing glucagon-like 
peptide 1 (GLP1)-agonist exenatide, it was shown 
that exenatide treatment was associated with a 
reduced decline in motor dysfunction in PD pa-
tients6. Specifically, once-weekly injections of the 
slow release form of exenatide for 48 weeks result-
ed in improvements in the MDS-UPDRS (part III)-
defined primary endpoint with effects persisting 
after a 12-week wash out period6. In a post hoc 
analysis evaluating non-motor symptoms, second-
ary end points such as patient and observer-led 
scales assessing mood also showed positive effects 
from the treatment7. Exenatide is currently in a 
Phase III trial in 200 PD patients who will be treated 
for 2 years, with the primary endpoint focused on 
disease modification (ClinicalTrials.gov identifier 
NCT0423296).   
A second insulin sensitizer that has been asso-
ciated with a lower risk of PD is pioglitazone3,4. 
However, when evaluated in a phase 2 clinical PD 
trial, pioglitazone did not have any significant effect 
on disease progression as measured via MSD-
UPDRS (part III)8. Pioglitazone belongs to a class of 
anti-diabetic drugs, termed thiazolidinediones or 
TZDs, and was believed to exert its anti-diabetic 
effects via activation of the transcription factor 
peroxisome proliferator-activated receptor- 
(PPAR). Due to strong binding of pioglitazone to 
PPAR the drug has several negative side effects. As 
a result, PPAR-sparing TZDs, including MSDC-0160 
were developed. Interestingly, when compared to 
pioglitazone, MSDC-0160 has similar anti-diabetic 
effects but it does not activate PPAR, indicating 
that TZDs act on a different receptor to elicit ef-
fects. The primary target was later found on the 
inner membrane of mitochondria and was identi-
fied as the previously unknown mitochondrial py-
ruvate carrier (MPC)9.   
Because of the link between TZDs and a low-
ered associated risk of PD, MSDC-0160’s limited 
side effects and its bioavailability in brain, we pre-
viously tested it in cell and animal models of PD 
and found that MSDC-0160 is neuroprotective10. 
Specifically, MSDC-0160 protects against dopamin-
ergic cell loss in the substantia nigra in neurotoxin-
challenged mice and in a genetic mouse model with 
hemizygous loss of the transcription factor En-
grailed 1 (En1), which is believed to entail mito-
chondrial deficits11. We also observed a mitigation 
of neuron death of MSDC-0160 treatment in Cae-
norhabditis elegans (C. elegans) in which we over-
expressed αSyn. Taken together, we hypothesized 
that the beneficial effects of MSDC-0160 were due 
to its anti-inflammatory effects and its ability to 
normalize metabolic deficits.  
The effects of MSDC-0160 on αSyn aggrega-
tion in progressive, chronic PD models have previ-
ously not been investigated. In this study, we there-
fore evaluated MSDC-0160 in two different α-syn 
based rodent models of PD; 1) a rat model with 
adeno-associated virus (AAV) vector over-
expression of human αSyn and 2) a mouse αSyn 
pre-formed fibril (PFF) seeding model. Unexpected-
ly, we found that MSDC-0160 increased the levels 
of aggregated αSyn in the AAV-overexpression 
model, possibly via increased oxidation of soluble 
αSyn. In the PFF seeding model, MSDC-0160 also 
increased αsyn burden transiently; a significant 
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difference between the treatment groups was ob-
served five weeks after PFF injection, but it was not 
present at the later 13-week timepoint. We exam-
ined both models further for inflammatory and 
lysosomal markers, and found them both to be 
unaltered, even in the presence of robust αSyn 
pathology. We conclude that while neuroprotective 
actions of MSDC-0160 may occur via restoring in-
flammatory and metabolic deficits, we could not 
demonstrate effects on protein aggregation or pro-




Twelve-week-old male and female C57BL/6J 
wildtype (WT) mice were sourced from The Jackson 
Laboratory. Eight-week old female rats were ob-
tained from Charles River. Animals were housed 
with a maximum of four mice or two rats per cage 
under 12-h light/12-h dark cycles with free access 
to food and water. For a direct comparison of 
MSDC-0160 and pioglitazone biodistribution of 
their metabolites in vivo, MSDC-0160 and pioglita-
zone were administered via oral gavage for 3 days 
for a dose of 30mg/kg/day. Collection of plasma, 
CSF and brain mitochondria was performed after 
day 3. For the chronic administration of MSDC-
0160, mice and rats were fed a diet of chow formu-
lated to deliver MSDC-0160 (30 mg/kg) or control 
chow starting at 1 week after stereotactic surgery. 
Mice were euthanized at two different time points: 
one and three months after PBS/PFF injections. Rat 
were euthanized four months after viral transduc-
tion. The housing of animals and all procedures 
were performed in accordance with the Guide for 
the Care and Use of Laboratory Animals (United 
States National Institutes of Health) and were ap-
proved by the Van Andel Research Institute's Ani-
mal Care and Use Committee.   
PFF production and OB injections 
Mouse αSyn PFFs were produced as described 
previously12. Before surgery, PFFs were prepared by 
the sonication of αSyn aggregates in a water-bath 
cup-horn sonicator for four min (QSonica, Q700 
sonicator, 50% power, 120 pulses 1 s ON, 1 s OFF). 
Mice were anesthetized with isoflurane/oxygen 
and injected unilaterally in the right olfactory bulb 
with either 0.8 µL of PFF (5 µg/µl; n=36, 18 fe-
males/males) or 0.8 µL of PBS as a control (n=36, 
18 females/males). Coordinates from bregma: AP: + 
5.4 mm; ML: +/- 0.75 mm and DV: - 1.0 mm from 
dura. Injections were made at a rate of 0.2 µL/min 
using a glass capillary attached to a 10 µL Hamilton 
syringe. After injection, the capillary was left in 
place for three min, before being slowly removed.   
Viral vector production and nigral surgeries 
rAAV2/5-CMVSyn-human-αSyn and rAAV2/5-
CMVSyn-GFP production was performed as de-
scribed previously13. Genome copies were deter-
mined via qPCR and two viral vector titers were 
used for injection into the rat SN. Nigral injections 
were performed under general anesthesia using an 
isoflurane/oxygen mixture. For the αSyn low dose 
and αSyn high dose a total of 1.2x1011GC and 
2.5x1011GC were injected, respectively. As a con-
trol, 3x1011GC of GFP expressing viral vector or PBS 
were injected. Coordinates from bregma: AP: 5.3 
mm, ML: 2.0 mm and DV: 7.2 mm measured from 
dura14. A volume of 3 µl of viral vector was infused 
at a rate of 0.25 µl/min using a 30G needle and 10 
µl Hamilton syringe.  
MSDC-0160 metabolite analysis 
Mice and rats were allowed free access to 
chow containing either MSDC-0160 (30 mg/kg) or 
placebo for up to four months. For mice, whole 
blood was collected five and 13 weeks post-surgery 
from the submandibular vein in 6 mL BD hepa-
rinized tubes. For rats, whole blood was collected 
in identical tubes via cardiac puncture four months 
after viral vector injection. The samples were cen-
trifuged for 15 min at 4°C (2000 x g), followed by 
collection of the supernatant (plasma) which was 
snap frozen and stored at -80°C. For collection of 
brain mitochondria, brain was isolated and homog-
enized via Dounce homogenization in a sucrose 
homogenization buffer (225 mM sucrose, 6 mM 
K2HPO4, 5 mM MgCl2, 20 mM KCl and 2 mM EG-
TA). Samples were centrifuged at 750g to remove 
cell debris followed by a second step of centrifuga-
tion at 15,800g. The resulting pellet was resus-
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pended in acetone to dry and collected in control 
plasma to store at -20˚C for future analysis.  
Frozen heparinized plasma samples were 
blind-coded and analyzed by Charles River Labora-
tories (Mattawan, MI) for the concentrations of the 
MSDC-0160 metabolite MSDC-0037 in Study Proto-
col 1443-007B. In short, each 25 μL aliquot of 
standard, QC sample, or study sample was mixed 
with 10 μL of working internal standard solution 
(1,250 ng/mL in methanol/water [50/50, v/v]) and 
140 µL of water. The samples were vortexed and 
transferred to an ISOLUTE SLE plate and eluted with 
1.0 mL of MTBE. The samples were evaporated and 
reconstituted with 100 µL of methanol followed by 
100 µL of 5 mM ammonium formate in water. The 
samples were mixed and transferred to a clean 96-
well plate. An aliquot was injected onto an LC 
MS/MS system for analysis. The liquid chromatog-
raphy system used a MacMod Ace 3 C18 column, 
2.1 x 50 mm (3 μm particle size) with a gradient 
flow consisting of 5 mM ammonium formate in 
water/methanol (75/25, v/v) and 5 mM ammonium 
formate in methanol/acetonitrile/water (72/18/10, 
v/v/v) at a flow rate of 500 µL/minute.   
The analyte, metabolite, and internal standard 
were detected using a SCIEX API 5000 triple quad-
rupole LC MS/MS system equipped with an ESI 
(TurboIonSpray®) ionization source operated in the 
positive ion mode. The multiple reaction monitor-
ing transitions of the respective [M+H]+ ions were 
used to monitor MSDC-0160 and MSDC-0037 as 
have previously been described for clinical stud-
ies15. 
Western blotting 
Rats were euthanized with sodium pentobar-
bital (130 mg/kg; Sigma) and transcardially per-
fused with PBS to remove blood. Brains were iso-
lated and the substantia nigra was dissected on ice 
using a rat brain matrix. Isolated samples were 
snap frozen and stored at -80 ˚C for later analysis. 
Frozen tissue was weighed in equilibrated Eppen-
dorf tubes and homogenized in PBS 10% w/v with 
protease and phosphatase inhibitors (ThermoFish-
er). Homogenization was performed by probe soni-
cation at 4 ˚C for 2 rounds of 15 s pulses at 0.5 Hz 
with a 10% amplitude. The whole homogenates 
were centrifuged for 10 min at 6000 x g at 4 ˚C. The 
pellet was discarded and supernatant was collected 
for analysis. To isolate insoluble αSyn, 20% sarkosyl 
was added to the whole homogenate to result in a 
1% sarkosyl PBS sample that was incubated on a 
rotating shaker for 1 h at room temperature. After 
incubation, samples were centrifuged for 10 min at 
6000 x g at 4˚C to remove remaining cell debris. 
The cleared supernatant was centrifuged at 
100,000 x g for 60 min and the resulting pellet was 
gently washed in PBS after which it was resuspend-
ed in 1% sarkosyl in PBS with protease and phos-
phatase inhibitors. A second centrifugation step at 
100,000 x g for 10 min was performed to collect the 
1% sarkosyl insoluble pellet. Protein concentrations 
were estimated using a BCA kit (Thermo Fisher). 
Samples were prepared with Laemmli buffer con-
taining 2% SDS, heated at 95˚C for 10 min for dena-
turation and stored at -80˚C. Protein samples were 
separated via 4-15% SDS PAGE (BioRad) and trans-
ferred to a PVDF membrane using the BioRad Tur-
boblot system. PVDF membranes were blocked 
with 5% BSA in PBS during 30 min at room temper-
ature. Overnight incubation with primary antibody, 
Iba-1 (1:500, WAKO), human αSyn (4B12, 1:1000, 
BioLegend), pSer129-αSyn (pS129, 1:5000, Abcam), 
LAMP1 (1:1000, Abcam), caspase (1:500, Abcam) 
was followed by incubation with HRP-conjugated 
secondary antibody (Cell Signaling Technology). 
Signal was detected by chemiluminescence (Pico 
Chemiluminescent Substrate, Thermo Fisher) using 
a BioRad Imager. Western blot bands were quanti-
fied using ImageJ software.  
Behavioral analysis 
To monitor functional deficits related to nigral 
dopamine neuron dysfunction and death, rats were 
subjected to a cylinder test to evaluate spontane-
ous forelimb use. Rats were placed in a clear glass 
cylinder and were filmed for a total of 30 contacts 
with the cylinder. Percentage of forepaw use was 
expressed as the percentage of right forepaw 
touches over total number of touches. Non-
lesioned rats score around 50%.  
To examine olfactory function in mice, the 
buried pellet test was carried out as recently de-
scribed by our laboratory in Johnson et al.16 In 
short, the mice were fasted overnight starting 
three days prior to testing. Throughout the experi-
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ment, their body weight was monitored and mice 
who lost more than 10% of their original body 
weight were excluded from further fasting and 
from the experiment. At the first day of testing, a 
surface test was performed, where the treat (Bio-
Serv, Fruit Crunchies) was placed on top of the 
clean bedding. Mice who were not motivated to 
eat the treat were excluded from further testing 
(all mice in this study were motivated by the treat 
and were thus included). For four consecutive days, 
the treat was buried at different locations 1 cm 
under the clean bedding and latency for mice to 
uncover it was recorded. A maximum time was set 
at 300 s, and if a mouse did not uncover the treat 
within that time frame, 300 s was recorded as its 
latency. The average latency to uncover the treat 
per animal is presented here, with nine to ten ani-
mals analyzed per group. 
Immunohistochemistry 
Mice and rats were euthanized with sodium 
pentobarbital (60 mg/mL; Sigma) and transcardially 
perfused with room temperature 0.9% saline fol-
lowed by ice-cold 4% paraformaldehyde (PFA) in 
0.1 M phosphate buffer. Brains were removed, 
post-fixed overnight at 4°C in 4% PFA and subse-
quently placed in 30% sucrose. Brains were frozen 
and coronal sections of 40 µm were cut on a micro-
tome (Leica) and collected as serial tissue sections. 
For immunohistochemistry in mice, a series (every 
240 µm) of coronal free-floating sections were 
stained using 1:10000 anti-pSer129 αSyn primary 
antibody (Abcam, Ab51253), 1:1000 anti-NeuN 
primary antibody (Millipore, Ab377), 1:5000 anti-
nitrated αSyn primary antibody (Thermo Fisher, 35-
8300) or 1:800 anti-Iba1 primary antibody (Wako, 
019-19741) over night. For immunohistochemistry 
in rats, a series (every 240 µm) of coronal free-
floating sections of SN was stained using 1:10000 
anti-pSer129 αSyn primary antibody (Abcam, 
Ab51253), 1:5000 anti-nitrated αSyn primary anti-
body (Thermo Fisher, 35-8300), 1:2000 anti-TH 
(Abcam, ab137869), or 1:800 anti-Iba1 primary 
antibody (Wako, 019-19741) overnight. Corre-
sponding secondary antibodies (1:500 goat anti-
rabbit/goat anti-mouse biotinylated secondary 
antibody (Vector Laboratories, BA-1000 and BA-
9200) were added. The antibody signal was ampli-
fied using a standard peroxidase-based method 
(VectaStain ABC kit) and developed using a DAB kit 
(Vector Laboratories). Immunostained tissue sec-
tions were mounted onto gelatin coated glass 
slides. NeuN- and TH-immunostained slides were 
counter stained with cresyl violet (CV). After dehy-
dration, slides were sealed by coverslip with Cyto-
seal 60 mounting medium (Thermo Fisher Scien-
tific).   
For LAMP2 immunostaining, using fluores-
cence to detect antibody binding, sections were 
incubated overnight with 1:1000 anti-LAMP2 pri-
mary antibody (Abcam, Ab13524) overnight, fol-
lowed by a 2 h incubation with a fluorescent sec-
ondary antibody (Thermo Fisher/Invitrogen, Alexa 
Fluor 488). DAPI was used to visualize cell nuclei. 
For the co-stain between h-FTAA and pSer129, 
tissue sections were incubated with 1:1000 anti-
pSer129 αSyn primary antibody (Abcam, Ab51253) 
for 2h at RT followed by a 1h incubation with 1:200 
secondary goat anti-rabbit antibody Alexa 647 
(Thermo Fisher, A32733) and DAPI to visualize cell 
nuclei. Finally, 0.5 µM h-FTAA was added and al-
lowed to incubate with the tissue for 30 min at RT. 
Fluorescently stained tissue was sealed by coverslip 
using hard-set antifade mounting media (Vector 
Laboratories, H-1400). A Nikon A1plus-RSi Laser 
Scanning Confocal Microscope (Nikon) was used to 
image these sections. 
pSer129 quantification 
Z-stacks of mounted αSyn pSer129-stained tis-
sue sections were captured at 20x magnification 
using a whole slide scanner (Zeiss, Axioscan Z1) at a 
0.22 m/pixel resolution. Extended depth focus 
(EDF) was used to collapse the z-stacks into 2D 
images as they were collected. Tissue thickness was 
set to 20 m, z-stacks were collected at 3 m inter-
vals and the method used was Contrast. The imag-
es were exported with 85% compression as .jpeg 
files. The digitized images were then uploaded Ai-
foria™ image processing and management platform 
(Aiforia Technologies, Helsinki, Finland) for analysis 
with deep learning convolution neural networks 
(CNNs) and supervised learning. A supervised, mul-
ti-layered, CNN was trained on annotations from 
digitized αSyn pSer129-stained coronal slices to 
recognize total αSyn-positive staining. The algo-
rithm was trained on the most diverse and repre-
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sentative images from across multiple pSer129 
datasets to create a generalizable AI model capable 
to accurately detecting αSyn pSer129-stained pro-
files in slides collected by multiple investigators. 
Ninety-one images constituted training data. The 
ground truth, or features of interest used to train 
the AI model, were annotated for each layer within 
the Aiforia™ Cloud platform and constituted input 
data for each CNN. The first feature layer was an-
notated using semantic segmentation to distinguish 
the total tissue from the glass slide. The second 
feature layer was annotated using semantic seg-
mentation to distinguish total αSyn pSer129-
positive staining. Features that were considered 
artifact (glass slide, debris) were annotated as 
background, and constituted additional input train-
ing data for the multi-layered CNN. The regions 
corresponding to the AON and the PRh were out-
lined according to the Allen Mouse Brain Atlas (Al-
len Institute) and the CNN was used to quantify the 
area percentage that contained αSyn pSer129-
positive signal. For each brain region, the average 
area with αSyn pSer129-staining is reported as a 
percentage of the whole area assayed. For the one-
month time point, six animals per group were ana-
lyzed and for the three-month time point seven to 
eight animals per group were included in the analy-
sis.   
Stereology 
Surviving dopamine neurons and total neu-
ronal cell counts were quantified using unbiased 
sampling and blinded stereology. For the AAV αSyn 
over-expression model, tyrosine hydroxylase (TH), 
αSyn pSer129 and nitrated αSyn-positive cells were 
counted in the SNpc and SNpr in a series of seven 
sections at an interval of six sections at 40 µm 
thickness (240 µm intervals). Contours of the re-
gions were drawn at 10x magnification and quanti-
fications were performed at 60x using a 200 µm 
counting frame. Dissector height was 12 µm with a 
3 µm guard zone. The Gunderson estimated m=1 
error was less than 0.1 and a total of eight animals 
per group was counted. For the αSyn PFF seeding 
model, NeuN- and CV-positive cells were counted 
in the AON, which was outlined according to the 
Allen Mouse Brain Atlas (Allen Institute) using a 
2.5x objective. The quantification of NeuN and CV-
positive cells was performed on every 6th AON (240 
µm) section using the optical fractionator probe in 
Stereo Investigator software (MBF Bioscience). The 
counting was accomplished using a 60x oil objec-
tive, with the grid set to 200x200 and the frame set 
to 40x40. The dissector height used was 10 µm, 
with a 3 µm guard zone. The Gunderson estimated 
m=1 error was less than 0.1 and a total of nine to 
ten animals per group were counted.  
Assessment of microglia morphology 
Microglia hydraulic radius (area/perimeter ra-
tio) was investigated as previously described13. In 
short, color (RBG) images were generated using a 
60x oil objective. Following imaging, a custom 
MATLAB script assessed the morphology of the 
imaged microglia, calculating the area/perimeter 
ratio. For the PFF seeding model, five to six animals 
per group were analyzed. Microglia were imaged 
from every 6th AON section and a minimum of 30 
individual microglia was analyzed per animal, with 
the average microglia area/perimeter ratio report-
ed.   
Quantification of fluorescent LAMP2 signal 
Images corresponding to the AON were cap-
tured using a 20x oil objective on a Nikon A1plus-
RSi Laser Scanning Confocal Microscope (Nikon) in 
a blinded manner. The area percentage occupied 
by LAMP2 positive signal was quantified using FIJI 
software (Nation Institute of Health) after an unbi-
ased threshold was applied. The average area per-
centage calculated for each animal is reported 
here. For the PFF seeding model, a total of six mice 
per group were analyzed. 
Statistics 
All AAV and PFF mouse model data were ana-
lyzed using R v3.6.0 (https://cran.r-project.org/) 
and assumed two-sided hypothesis tests with a 
significance level <0.05 after Benjamini-Hochberg 
multiple testing corrections. In the PFF model, neu-
ronal cell count, Iba1 and pSer129 quantification 
were done in parallel with another treatment 
group (PT302, data not shown), meaning they 
share the same set of placebo treated animals; the 
multiple testing corrections take into account these 
additional comparisons. For experiments that ana-
Free Neuropathology 1:33 (2020) Peelaerts et al 




lyzed both hemispheres of the brain independently 
(e.g. ipsilateral versus contralateral) the appropri-
ate mixed-effects model was used (R package lme4 
https://cran.r-project.org/web/packages/lme4/ind
ex.html unless otherwise noted). Count data were 
analyzed using negative binomial regressions; 
mixed-effects negative binomial regressions were 
done using the R package glmmTMB and the 
‘nbinom1’ family (https://cran.r-project.org/web/
packages/glmmTMB/index.html). Time-to-event 
data (e.g. the buried pellet test) were analyzed 
using Cox proportional hazards regression. All other 
data types were analyzed via linear regression with 
log and square-root transformed outcomes as 
needed based on standard regression diagnostics 
(i.e. normality of residuals and homoscedasticity) 
(log: IF αSyn pSer129 and soluble αSyn; square-
root: soluble αSyn pSer129, insoluble human αSyn, 
insoluble αSyn pSer129). Cook’s distance was used 
to assess individual observations with high 
amounts of leverage (set as 4/(n-p-1)). For linear 
regressions with highly influential observations, 
robust regressions with MM estimation were used. 
Zero variance data (i.e. DAB αSyn pSer129+, IF αSyn 
pSer129+, soluble human αSyn, and Nissl+ 
measures across both naive and GFP injected ani-
mals), logistic regression with a Firth correction was 
used to determine if the odds of detection versus 
no detection differed between groups. An equiva-
lence interval of +/-10% was used to determine if 
groups had strong evidence for equivalence based 
on their 95% confidence intervals.  
Results  
Inhibiting the MPC in a viral vector-based model 
of human α-syn overexpression 
To determine the effects of inhibiting the MPC 
on αSyn aggregation, we used a slowly progressing 
viral vector-based model that overexpresses αSyn. 
We selected two doses of viral vector, which from 
here on will be referred to as ‘αSyn low’ 
(4.3x1013GC/ml) and ‘αSyn high’ (8.6x1013GC/ml). 
These two titers yield a 4- and 6-fold overexpres-
sion of αSyn in rat SNpc, respectively (Fig. 1A, 3B).  
Female rats were stereotactically injected in 
SNpc at 8 weeks of age with rAAV2/5 CMV-Syn-
αSyn or rAAV2/5 CMV-Syn-GFP expressing vector 
that served as a control (Fig. 1A). One week post-
surgery, the animals were allowed free access to 
chow containing either MSDC-0160 (30mg/kg) or 
placebo for four months. In order to evaluate the 
uptake and distribution of MSDC-0160, we ana-
lyzed the levels of exposure of MSDC-0160, 
pioglitazone and its metabolites in rat plasma, CSF 
and brain mitochondria 20 hours after administra-
tion (Supplementary fig. 1). Hydroxymitoglitazone, 
the active metabolite of MSDC-0160, was found at 
higher levels, compared to pioglitazone metabo-
lites, in plasma and CSF. In brain mitochondria hy-
droxymitoglitazone was also found at higher levels 
then pioglitazone-OH or other metabolites, show-
ing its interaction with brain mitochondria but also 
suggesting that the interaction of MSDC-0160 me-
tabolites with mitochondria is stronger compared 
to pioglitazone metabolites (Supplementary fig. 1). 
During the time of chow administration, we did not 
observe any differences in animal body weight or 
chow consumption (Supplementary fig. 2A, B). At 
the four-month timepoint, plasma was collected 
and the presence of hydroxymitoglitazone (MSDC-
0160 metabolite) was quantified (Supplementary 
fig. 2C), showing the presence and metabolization 
of MSDC-0160 at expected levels. 
Motor behavior was examined four months 
after viral transduction using the cylinder test. No 
difference in motor behavior was apparent be-
tween any of the experimental groups, nor did we 
observe any statistically significant differences be-
tween placebo or MSDC-0160 treated groups (Sup-
plementary fig. 3). When assessing the total num-
ber of TH- and Nissl-positive neurons in the SN via 
stereology we find a significant decrease in TH- and 
Nissl-positive cells between the αSyn high group 
and all other experimental treatment groups (Fig. 
1A-B), suggesting dose-dependent neurotoxic ef-
fects of αSyn expression. No cell loss was observed 
in the GFP group, showing that no toxic effects are 
due to the viral vector itself. In addition, when the 
SNpc is separately analyzed for its anterior (Bregma 
-4.8 mm) and posterior (Bregma -6.2 mm) areas, TH 
loss in the anterior is much more significant com-
pared to the posterior region (Supplementary fig. 4 
A-D). This indicates that αSyn expression from the 
overexpressing αSyn vector is higher in the anterior 
SNpc since it is adjacent to the injection site, and
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Fig 1. MSDC-0160 treatment does not influence nigral dopaminergic cell viability in a progressive αSyn overexpression model. a) 
Experimental overview of the αSyn viral vector overexpression model in rat SN. b) TH expression and Nissl+ cells in rat SN for animals 
treated with placebo or MSDC-0160 in control or experimental conditions. Scale bar = 500 µm. c) Stereological quantification of total 
dopamine neurons in rat SNpc for ipsi- and contralateral sides. The contralateral hemisphere had significantly more TH cells than the 
ipsilateral in the αSyn high mice (p = 0.001, ~22.5% more cells CI = 10.3% - 36.0%, negative binomial mixed-effect model, n = 8, s.e.m.). 
In the ipsilateral side, αSyn high had significantly fewer TH cells than Naïve, GFP and αSyn low (p = 0.031, 14.9% fewer CI = 4.8 – 23.9, *p 
= 0.05, 13.4% fewer 95% CI 3.1 - 22.6 and p = 0.0313, 15.6% fewer CI = 24.5- 5.6, respectively, negative binomial mixed-effect model, n = 
8, SEM). d) Stereological quantification of Nissl+ cells in rat SN for ipsi- and contralateral sides. For the αSyn high group, the ipsilateral 
side has ~ 13% fewer Nissl+ cells across both treatment groups than the contralateral (p < 0.0001, 95% CI 6.4 - 20.1, negative binomial 
mixed-effect model, n = 8, SEM). αSyn high shows significantly fewer Nissl+ cells compared to animals injected with naive, GFP, or low 
amounts of αSyn (p < 0.001 for all 3, GFP: 15% fewer CI = 8% - 21%, Naive: 18.4% fewer CI = 12.0% - 24.4%, αSyn low: 16% fewer CI = 
22.2% - 9.3%, negative binomial mixed-effect model, n = 8, SEM). 
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lower in the posterior portion, which again con-
firms vector-driven αSyn neurotoxic effects with no 
neurotoxicity observed for the GFP control group. 
Next, we performed stereological counts of 
nigral cells positive for phosphorylated αSyn (αSyn 
pSer129) (Fig. 2A). Unexpectedly, in the αSyn low 
group, animals treated with MSDC-0160 show sig-
nificantly more αSyn pSer129+ cells compared to 
the placebo group (12132 versus 7918 cells, **p = 
0.002, negative binomial regression with Benja-
mini-Hochberg multiple testing adjustments, SEM, 
n = 8) (Fig. 2B). No significant effect was detected 
in the αSyn high group between MSDC-0160 and 
the placebo group. 
We further analyzed phosphorylated levels of 
αSyn via biochemical analyses and found that both 
soluble αSyn pSer129 as well as 1% sarkosyl insolu-




Figure 2. A metabolic switch leads to increased αSyn patholo-
gy in rat SN. a) Overview of pSer129-αSyn positive cells in rat 
SN. Scale bars for higher and lower magnification represents 
450 µm and 100 µm, respectively. b) Stereological quantifica-
tion of Syn pSer129 positive cells in rat SN. Treatment with 
MSDC-0160 leads to a significant increase in phosphorylated 
cells in the αSyn low group compared to placebo (n = 8, SEM, 
**p < 0.01 and ***p < 0.001, negative binomial regression with 
Benjamini-Hochberg multiple testing adjustments, SEM, n = 8)). 
in the MSDC-0160 treated animals compared to the 
placebo group (*p = 0.046, 95% CI 0.039 – 0.471, 
square-root linear regression, SEM, n = 6 for solu-
ble αSyn pSer129 and *p = 0.013, 95% CI 0.129 – 
0.691, square-root linear regression, SEM, n = 6 for 
1% sarkosyl insoluble αSyn pSer129) (Fig. 3E, F). 
This increase was observed in the αSyn high group 
between MSDC-0160 and placebo animals whereas 
a similar trend was noticeable in the αSyn low 
group between treatment conditions (Fig. 3E, F). 
This indicates that administration of MSDC-0160 
results in increased αSyn aggregation in the slowly 
progressing viral vector-based model that overex-
presses αSyn. 
αSyn has been shown to bind the membrane 
of mitochondria17. Due to its membrane curvature 
and the presence of the negatively charged cardi-
olipin in the mitochondrial outer membrane, αSyn 
has a strong binding affinity for mitochondria18. 
Aggregated αSyn can disrupt mitochondrial mem-
brane integrity and lead to toxicity19. To examine 
why inhibiting the MPC results in more αSyn aggre-
gation, we investigated if altering mitochondrial 
function, or changing oxidative environment via 
MSDC-0160 affects αSyn binding or αSyn oxidation 
status. Stereological quantifications of the SNpc for 
nitrated ni-αSyn (ni-αSyn) shows that in the αSyn 
low group, inhibiting the MPC with MSDC-0160 
leads to more ni-αSyn (*p = 0.021, 95% CI 11.5% – 
111.7% more after negative binomial regression 
with Benjamini-Hochberg multiple testing adjust-
ments), indicating that inhibiting the MPC leads to 
increased oxidation of αSyn (Fig. 4). Since it has 
been shown that oxidation of αSyn can affect αSyn 
aggregation, it raises the possibility that in this 
αSyn overexpression model a metabolic switch 
promotes the formation of insoluble assemblies of 
αSyn by increasing αSyn oxidation. 
Since our previous work has shown that inhib-
iting the MPC has strong anti-inflammatory and 
metabolic effects, we further investigated if our 
αSyn viral vector model was lacking these features, 
which could explain the absence of any apparent 
therapeutic benefits. We examined changes in mi-
croglial and lysosomal markers at the four-month 
timepoint and found no changes in microglial acti-
vation (Fig. 5A-B, E) and no changes in markers of 
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Figure 3. αSyn aggregation is increased in rat SN after inhibition of the MPC. a) Inhibition of the MPC has no effect on viral vector-
mediated expression of GFP. b) Detection of total levels of αSyn in naïve and experimental conditions. αSyn overexpression leads to a 4- 
and 6-fold increase in αSyn low and high conditions compared to naïve rats. c,d) Isolation of sequentially extracted soluble and 1% 
sarkosyl insoluble human αSyn (1% hu-αSyn) shows no significant differences in aggregated αSyn after treatment with MSDC-0160. e,f) 
Inhibition of MPC leads to significantly increased levels of soluble and 1% sarkosyl insoluble Syn pSer129 (1% P129-αSyn) in the αSyn 




autophagy (LAMP1 and cathepsin D) in any of the 
groups examined (Fig. 5C, F-G). Taken together, in 
absence of metabolic or lysosomal deficits and 
microglial changes (at least at these later time 
points), a metabolic switch, by inhibiting the MPC, 
does not have a beneficial effect on αSyn aggrega-
tion. 
Inhibiting the MPC in a mouse PFF seeding model 
Next, to investigate the effects of inhibiting 
MPC on αSyn aggregation, we examined the effects 
of MSDC-0160 on αSyn propagation. We used a 
previously established seeding model where αSyn 
PFFs are unilaterally injected into the OB of 12-
week-old wild type mice. Over time, αSyn patholo-
gy will propagate via intraneuronal connections and 
cause pathology in upstream regions19,20. One-week 
 
Figure 4. Ni-αSyn increases upon MSDC-0160 treatment. 
Stereological quantification of ni-αSyn positive cells in rat SN. 
Treatment with MSDC-0160 leads to a significant increase in 
nitrated cells in the αSyn low group compared to placebo (*p < 
0.05 via negative binomial regression with Benjamini-Hochberg 
multiple testing adjustments, n = 8, SEM) 
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Figure 5. Absence of inflammatory or autophagy deficits in αSyn overexpressing animals. a) Overview of microglial morphology via 
Iba-1 staining in rat SN shows no microglial activation in αSyn overexpressing conditions. Scale bar = 50 µm. b) Quantification of micro-
glial hydraulic radius as a measure of microglial ramification and activation (n = 8, SEM). c) Representative Western blot images of in-
flammatory and autophagy markers in SN. d) Iba-1 and e) GFAP markers show no signs of inflammatory activation (n = 6, SEM). d) Ca-
thepsin-D and e) LAMP1 expression is unaltered in αSyn overexpressing animals (n = 6, SEM). 
 
 
post PFF or PBS injection into the OB, the mice 
were allowed free access to chow containing either 
MSDC-0160 or placebo (Fig. 6A). During the time of 
chow administration, we did not observe any dif-
ferences in animal body weight or chow consump-
tion between groups (Supplementary fig. 5A, B). At 
5- and 13-weeks post-surgery, plasma was collect-
ed and the presence of hydroxymitoglitazone 
(MSDC-0160 metabolite) was quantified (Supple-
mentary fig. 5C), showing detectable levels of the 
metabolite in treated groups. 
Unilateral PFF injections have previously been 
shown to impair olfactory function in mice20. Olfac-
tory function was thus examined 13 weeks post-
surgery using the buried pellet test. No significant 
difference was observed between the PBS and PFF 
groups, regardless of whether the mice had been 
treated with placebo or MSDC-0160 (Supplemen-
tary fig. 6A). When assessing the total number of 
NeuN and CV-positive cells in the AON 13 weeks 
post-surgery via stereological quantification, we 
found no significant differences between any of the 
experimental groups (Supplementary fig. 6B & C). 
Immunohistological assessment at 5- and 13-
weeks post-surgery revealed a significantly higher 
percentage area containing pathological αSyn 
(αSyn pSer129) in the AON than the PRh, regardless 
of time point and treatment group (8.5-16 times 
higher; all p ≤ 0.001) (Fig. 6B-E). The same was seen 
for the ipsilateral side compared to the contrala-
teral side (65-78% less on the contralateral side; p ≤ 
0.001). From 5 to 13 weeks post-surgery, 
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Figure 6. A metabolic switch increases αSyn pathology load and propagation in mouse AON and PRh. a) Experimental timeline; at 12 
weeks of age C57BL/6J mice were injected with PFFs or PBS and starting at one-week post-surgery they had free access to MSDC-0160 
or placebo containing chow until the 5- or 13-week endpoint. Quantification of Syn pSer129 positive signal in b) the AON and c) the 
PRh after 5 or 13 weeks of MSDC-0160 or placebo treatment. MSDC-0160 treated mice had significantly more Syn pSer129 positive 
stain at 5 weeks post-surgery than the placebo group (1.8 times more; p=0.02, 95% CI 1.176 - 2.824, Beta mixed-effects regression). 
There is also weak evidence that this persists at the 13-week timepoint (p=0.085, 95% CI 0.986-1.92, Beta mixed-effects regression). 
c) Quantification of Syn pSer129 positive signal in the PRh after one and three months of MSDC-0160 or placebo treatment. d) Repre-
sentative images of Syn pSer129 staining in d) the ipsilateral AON (scalebar = 130 µm) and e) the PRh (scalebar = 100 µm). 
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αSyn pSer129 increased significantly for MSDC-
0160 and placebo treated animals, which both 
gained ~99.2% and 163.2% of their αSyn pSer129 
immunopositively stained area from week 5 to 
week 13, respectively in the contralateral AON (p = 
0.016 and < 0.001, respectively, 95% CI = 19.2 - 
233.3 and 55.8 - 344.4). In addition, placebo-
treated animals had a significant increase of pa-
thology in the ipsilateral AON from the 5 to 13-
week timepoint (p=0.016, 95% CI 18.3% - 200%). 
This was not observed for MSDC-0160 treated 
mice. When comparing treatment groups, MSDC-
0160 treated mice had significantly more pSer129 
positive signal at 5 weeks post-surgery than the 
placebo group (1.8 times more; p=0.02 95% CI 1.16 
- 2.90). There is also weak evidence that this per-
sists at the 13-week timepoint (p=0.085, 95% CI 
0.98-1.95). No ni-αSyn was detected in the PFF 
seeding model at the 13-week timepoint (Supple-
mentary fig. 7).   
 
 
Figure 7. h-FTAA positive protein aggregates detected in the 
PFF seeding model but not the AAV overexpression model. 
Representative images of the AON and the SN for the PFF 
model and the AAV overexpression model, respectively. The h-
FTAA positive signal (green) detected in the AON 13 weeks 
following surgery co-localizes with the Syn pSer129 signal 
(pink). DAPI was used to visualize the cell nuclei (blue), scale 
bar = 10 µm and 3 animals per group were analyzed. 
 
 
For detection of potential amyloid (β-sheet 
rich) structures in the PFF seeding model and the 
AAV overexpression model, we used a luminescent 
conjugated oligothiophene (LCO). LCOs are small 
molecules with a flexible thiophene backbone that 
upon binding to amyloid structures become fluo-
rescent21. One such LCO, which has previously been 
shown to bind aggregates in tissue samples from 
patients suffering from systemic amyloidosis, as 
well as a variety of other disease-associated protein 
aggregates, is h-FTAA21 In the AON at 13 weeks 
post-surgery we observed ring-like h-FTAA positive 
structures (Fig. 7) in the PFF model. These over-
lapped with αSyn pSer129 antibody staining, indi-
cating that the αSyn pathology detected in this 
model is β-sheet rich with amyloid properties. On 
the contrary, we did not find a h-FTAA positive 
signal in the αSyn high group for the AAV overex-
pression model. This highlights differences in αSyn 
assembly states several weeks after surgery in the 
two PD rodent models. 
Given the absence of any therapeutic benefits 
in the PFF model, we again investigated the pres-
ence of inflammation via measuring the hydraulic 
radius (area/perimeter ratio) of microglia in the 
AON 13 weeks post-surgery. When we compared 
the injected side with the non-injected side, we 
found no significant change in microglia morpholo-
gy (Fig. 8A, B). Furthermore, we did not detect any 
significant difference between PBS and PFFs groups 
or differences between animals treated with place-
bo or MSDC-0160. In addition, by quantifying 
LAMP2-positive staining we do not observe any 
lysosomal deficits in the AON 13 weeks post-
surgery (Fig. 8C, D). Taken together, in absence of 
lysosomal deficits and microglial changes, a meta-
bolic switch, by inhibiting the MPC, does not re-
duce accumulation of αSyn pSer129 in mice inject-
ed with PFFs in the olfactory bulb. 
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Figure 8. Absence of inflammatory or autophagy deficits 13-weeks post PFF surgery. a) Representative images 
of Iba-1 positive staining in the ipsilateral AON, scale bar = 50 µm. b) Quantification of microglial hydraulic ra-
dius as a measure of microglial ramification and activation (n = 5-6/group, SEM), shows no microglial activation 
following PFF injection. c) Representative images of LAMP2 positive staining (green) in the ipsilateral AON. DAPI 
(blue) was used to visualize the cell nuclei. Scale bar = 10 µm d) Fluorescent LAMP2 quantification after adding 
adaptive triangle thresholding in the AON (n = 6, SEM) 
 
Discussion 
Improving metabolism, reducing inflammation and 
inhibiting the aggregation or the spread of patho-
logical αSyn are considered promising therapeutic 
targets for the treatment of PD. Through preclinical 
and clinical work, it has been suggested that anti-
diabetic drugs might hold this promise22. We have 
previously shown that MSDC-0160, a type 2 diabe-
tes insulin sensitizer, can ameliorate pathology in 
an acute (1-methyl-4-phenyl-1,2,3,6-tetrahydro
pyridine, MPTP) and slowly progressive, genetic 
(Engrailed1+/-) model of PD and that these effects 
occurred via modulation of the MPC and its down-
stream effect involving the mTOR pathway10. Since 
the direct effects of inhibiting MPC in chronic mod-
els of αSyn aggregation had not been studied, we 
asked if MSDC-0160 could lower the levels of αSyn 
in two different, chronic and progressive αSyn-
based animal models of PD. In our first model, αSyn 
is expressed via viral vector delivery in the rat SN 
resulting in aggregation and progressive accumula-
tion of insoluble αSyn. After four months, no signif-
icant motor abnormalities with moderate neuro-
degeneration were observed but, unexpectedly, 
animals that were treated with MSDC-0160 exhib-
ited increased levels of aggregated αSyn. In the 
second model, PFFs were injected in the OB of mice 
and allowed to seed and spread to connected re-
gions. Five weeks after PFF injection, we observed 
an increase in αSyn pathology burden when mice 
were treated with MSDC-0160. This effect was 
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transient and at the later, 13-week timepoint no 
significant difference between the two treatment 
groups could be observed.   
Both the αSyn viral vector and the αSyn PFF 
seeding models are based on the introduction of 
exogenous αSyn that leads to progressive accumu-
lation of phosphorylated and misfolded αSyn over 
time. The viral vector model results in local accu-
mulation of highly concentrated but soluble αSyn 
that assembles into insoluble αSyn, whereas the 
PFF model is based on the introduction of aggre-
gated, seeding-potent αSyn that relies on the en-
dogenous protein to template and spread via ana-
tomically connected regions. To date, there are no 
studies that have directly compared the assembly 
states of the αSyn in the intraneuronal inclusions 
that remain after several weeks in an overexpres-
sion versus a seeding model, but it appears that 
inhibiting the MPC has different outcomes in these 
two models. This tentatively suggests i) that the 
conformational state or aggregation state of αSyn 
might be different in the two models and ii) that 
the effects of inhibiting the MPC depends on the 
assembly state of the protein. 
We observed a disparity in αSyn assembly 
states between the viral vector-based and the 
seeding model in multiple assays. First, we used 
detection of nitrated αSyn to determine that αSyn 
is oxidized in the viral vector-based model. A previ-
ous study showed that αSyn can bind directly to the 
mitochondrial import protein TOM20, which leads 
to increased mitochondrial respiration and ROS 
production17. We now find that oxidized αSyn spe-
cies are abundant in neurons in the viral vector 
model, but undetectable in the PFF model. We 
postulate that by altering the TCA cycle when treat-
ing mice overexpressing αSyn with MSDC-0160, the 
oxidation of αSyn is increased. This suggests that 
alterations in mitochondrial metabolism might 
post-translationally modify αSyn and make it more 
aggregation prone, when the protein is highly con-
centrated even though it is not known how exactly 
a metabolic switch would take place in αSyn over-
expressing neurons nor how it would affect αSyn 
aggregation during anaplerosis. Furthermore, we 
propose that elevated levels of soluble αSyn are 
required for these changes to take place, since we 
did not observe similar effects in the PFF seeding 
model where the endogenous levels of αSyn are 
normal and aggregates are formed via an induced 
seeding mechanism. Since the conformational state 
of αSyn is closely linked to its function23, it is possi-
ble that elevated levels of monomeric αSyn lead to 
changes in assembly state or gain of post-
translational modifications resulting in an aberrant 
interaction with mitochondria. The binding affinity 
of αSyn is higher for mitochondrial membranes due 
to the unique presence of cardiolipin in mitochon-
dria18. Lipid interaction is an important catalyst for 
soluble αSyn to convert into aggregated αSyn24 and 
this conversion has been reported to lead to re-
lease of mitochondrial nitric oxide and increased 
oxidative stress25. αSyn can disrupt membrane in-
tegrity and cause mitochondrial damage and de-
generation of dopaminergic neurons17,26. Recombi-
nant nitrated species of αSyn injected in rat SN 
have been shown to be more toxic than unmodified 
αSyn27. In MSDC-0160 treated mice, we did indeed 
observe greater loss of dopamine neurons in the 
anterior portion of the SN, which was the region 
where viral vector-mediated expression of αSyn 
was the highest.   
Multiple molecules of nitrated αSyn have 
been shown to form soluble assemblies that are off 
pathway to aggregation and relatively unstruc-
tured28. In order to determine if structured amyloid 
forms of αSyn were present in our animal models, 
we used the conformation sensitive LCO h-FTAA 
probe29. LCOs are amyloid-conformation-specific 
dyes that specifically bind to amyloid αSyn in brain 
tissue and CSF30. A positive signal therefore indi-
cates the presence of well-structured, β-sheet rich 
aggregated αSyn. In addition, h-FTAA has been 
used to distinguish protein inclusion bodies in spo-
radic inclusion body myositis (s-IBM) and liver dis-
eases21. Upon treatment with h-FTAA, we observed 
a strong positive signal in the AON of animals in-
jected with PFFs but no signal in the SNpc of ani-
mals overexpressing αSyn following viral vector 
injection. The fluorescent signal was localized to 
neurons and the morphology was Lewy body-like 
with aggresomal structures that resembled the 
intracellular distribution we observed when stain-
ing for αSyn pSer129. This illustrates that the two 
αSyn animal models also differ in that the αSyn 
assembly states in these models are distinct. These 
differences were recently discussed by Gómez-
Free Neuropathology 1:33 (2020) Peelaerts et al 




Benito and colleagues; αSyn species from the AAV 
overexpression model lack seeding activity while 
the PFF model recapitulates αSyn propagation with 
the accumulation of Lewy body-like structures31.   
In summary, MSDC-0160 does not reduce 
αSyn aggregation in the model where a viral vector 
is used to overexpress the protein in the nigrostria-
tal system. On the contrary, the inhibition of MPC 
results in a slight increase in αSyn protein content. 
In the model using injection of PFFs to trigger a 
cascade of αSyn aggregate propagation in the ol-
factory system, MSDC-0160 exhibits no effect on 
the progressive development of synucleinopathy in 
the olfactory system. In experimental paradigms 
that involve more acute neuroinflammation, we 
previously showed that MSDC-0160 alleviates the 
inflammatory response in vitro and in vivo10. How-
ever, in the PFF and viral vector αSyn models, we 
did not detect changes in inflammation or evidence 
for autophagy deficits at the survival times we 
studied. We conclude that attenuation of the MPC 
in rodent models that do not exhibit inflammation 
and limited autophagy does not result in a reduc-
tion of introduced αSyn. 
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